Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFenner PLC Regulatory News (FENR)

  • There is currently no data for FENR

Acquisition

2 Feb 2015 07:00

RNS Number : 6949D
Fenner PLC
02 February 2015
Β 

02 February 2015

Fenner PLC ("Fenner")

Acquisition of Charter Medical Limited ("Charter")

Fenner is pleased to announce that its wholly owned subsidiary Fenner Drives, Inc. has acquired 100% of the share capital of Charter from its parent company Lydall, Inc. a publicly traded company (NYSE: LDL) headquartered in Connecticut. Charter will be integrated into Solesis Medical Technologies ("Solesis"), part of Fenner's AEP division.

The consideration of US$29.9m was satisfied in cash at completion and the transaction is expected to be earnings enhancing immediately upon acquisition.

Charter manufactures specialty single-use assemblies and Class I and Class II medical devices for the collection, processing, storage and filtration of biological and bioprocessing fluids. Charter also produces bio-containers and fluid management sets that serve a range of life science applications including biopharmaceutical manufacturing, cell therapy and cryogenic storage. Charter is a single site company based in Winston-Salem, North Carolina.

As at 31 December 2014, unaudited gross assets acquired were US$6.9m with underlying EBITDA (1) of US$3.3m for the 12 months to 31 December 2014 on sales of US$19.6m.Β 

The entire workforce of Charter have become employees of Fenner upon completion and will continue to be led by General Manager, Mr. Gael Peron.

Nick Hobson, CEO of Fenner PLC, commented:

"In common with all businesses in our AEP division, Charter applies its polymer technology to solving problems in performance-critical applications. Charter has a strong, established business in blood transfusion and filtration markets and has exciting opportunities in the bio-processing and regenerative medicine markets, in which Fenner is already active and which are experiencing rapid growth.Β 

The acquisition of Charter, which will provide an attractive addition to the capabilities and offerings of Solesis, continues Fenner's strategy to develop our medical business both organically and by acquisition."

For further information please contact:

Β 

Fenner PLC 01482 626501

Nick Hobson, Chief Executive

John Pratt, Finance Director

Β 

Weber Shandwick Financial 020 7067 0700

Nick Oborne / Tom Jenkins

Β 

Β 

(1) Adjusted for historic non-recurring items

Β 

Notes to editors:

Β 

Fenner PLC is a world leader in reinforced polymer technology, providing local engineered solutions for performance-critical applications. The Group operates through two divisions:

Engineered Conveyor Solutions:Β the ECS division, trading under the Fenner Dunlop, Fenner and Dunlop brand names, is a recognised leader in the global conveying market. The division offers a unique, comprehensive suite of products and services, which serve the conveying needs of mining, power generation and bulk handling markets.

Advanced Engineered Products:Β the AEP division uses advanced polymeric materials and technical expertise to provide high value-added solutions to customers' most challenging engineering problems. Customers are spread across a variety of end-user segments, including oil & gas and medical which account for some 40 per cent of divisional revenue, together with construction, transportation, automation and general industrial. AEP's trading names are recognised globally and include CDI Energy Products, EGC Critical Components, Hallite, AIP Precision Machining, Fenner Precision, Fenner Drives, James Dawson, Mandals, Secant Medical and Xeridiem.

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
ACQUARWRVBAURAR
Date   Source Headline
2nd Mar 20129:20 amRNSHolding(s) in Company
1st Mar 20122:45 pmRNSBlocklisting Interim Review
24th Feb 201211:21 amRNSDirector/PDMR Shareholding
17th Feb 20124:18 pmRNSHolding(s) in Company
16th Feb 20124:19 pmRNSHolding(s) in Company
1st Feb 20123:57 pmRNSDirector/PDMR Shareholding
19th Jan 20123:07 pmRNSResult of AGM
16th Jan 20123:18 pmRNSHolding(s) in Company
11th Jan 20127:00 amRNSAGM and IMS
9th Jan 20122:44 pmRNSHolding(s) in Company
4th Jan 201211:32 amRNSAnnual Information Update
8th Dec 20112:10 pmRNSDocuments available for Inspection/Notice of AGM
6th Dec 201111:41 amRNSHolding(s) in Company
1st Dec 20117:00 amRNSAcquisition
30th Nov 201110:41 amRNSTotal Voting Rights
24th Nov 20113:41 pmRNSDirector/PDMR Shareholding
22nd Nov 201110:21 amRNSDirector/PDMR Shareholding
21st Nov 20114:34 pmRNSHolding(s) in Company
18th Nov 201110:41 amRNSDirector/PDMR Shareholding
15th Nov 201110:22 amRNSAdditional Listing
9th Nov 20117:00 amRNSFinal Results
26th Sep 20111:37 pmRNSHolding(s) in Company
19th Sep 20111:12 pmRNSDirector Declaration
6th Sep 20117:00 amRNSPre-Close Trading Update
2nd Sep 20119:23 amRNSBlocklisting Interim Review
1st Sep 20117:00 amRNSCompletion of Acquisition
24th Aug 201112:33 pmRNSHolding(s) in Company
23rd Aug 20117:00 amRNSAcquisition
4th Aug 20113:38 pmRNSDirector/PDMR Shareholding
18th Jul 20117:00 amRNSInterim Management Statement
4th Jul 20117:00 amRNSAcquisition
8th Jun 201111:37 amRNSDirector/PDMR Shareholding
31st May 20119:45 amRNSTotal Voting Rights
27th May 20112:23 pmRNSUS$200 million Private Placement
4th May 20117:00 amRNSAdditional Listing
28th Apr 201111:30 amRNSAcquisition
27th Apr 20117:00 amRNSHalf Year Results
13th Apr 20113:29 pmRNSHolding(s) in Company
7th Mar 20117:00 amRNSPre-Close Trading Update
2nd Mar 20113:15 pmRNSRe Board Changes
1st Mar 201111:35 amRNSBlocklisting Interim Review
28th Feb 20119:32 amRNSTotal Voting Rights
24th Feb 20112:01 pmRNSDirector/PDMR Shareholding
24th Feb 20111:53 pmRNSDirector/PDMR Shareholding
17th Feb 20114:35 pmRNSPDMR Shareholding PSP
9th Feb 201110:14 amRNSAdditional Listing
28th Jan 201110:00 amRNSHolding(s) in Company
14th Jan 20112:05 pmRNSResult of AGM
12th Jan 20117:00 amRNSAGM and IMS
10th Jan 20112:31 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.